We interviewed GraniteShares' CEO Will Rhind from New York, soon after they launched a suite of ETP's which allow you to invest in three different baskets of giant US tech stocks. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 222.50
Bid: 222.00
Ask: 222.50
Change: -14.50 (-6.12%)
Spread: 0.50 (0.23%)
Open: 235.00
High: 235.00
Low: 222.00
Yest. Close: 237.00
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Syncona portfolio company Freeline prices US IPO

Fri, 7th Aug 2020 08:17

(Sharecast News) - Healthcare investment company Syncona announced on Friday that its portfolio company Freeline Therapeutics has priced its initial public offering in the United States.
The FTSE 250 company said the offering would consist of 8,823,529 American depositary shares, at a price of $18 each, raising total gross proceeds of about $158.8m (£120.8m).

All depositary shares sold in the IPO were offered by Freeline, with each representing one ordinary share.

The shares are expected to begin trading on the Nasdaq Global Select Market on Friday, under the ticker symbol 'FRLN'.

Following the IPO, Syncona said it would retain a stake of 49% in Freeline, amounting to 18,814,527 ordinary shares, with a total value of £257.7m, having agreed to invest $24.3m in the IPO.

That included an increase in the value of its current shareholding of £57.7m, compared to the 30 June reported value of £181.5m.

"In the five years since Syncona founded Freeline, the company has brought multiple programmes to the clinic, with a cutting-edge manufacturing platform and expert management team," said Syncona Investment Management chief investment officer Chris Hollowood.

"Today's milestone is a significant achievement for the business, and we look forward to continuing to work in close partnership with the management team as it looks to realise its ambition to deliver treatments to patients."

At 0817 BST, shares in Syncona were down 1.17% at 254p.

More News

LONDON MARKET MIDDAY: FTSE 100 hits 14-month high ahead of US jobs

LONDON MARKET MIDDAY: FTSE 100 hits 14-month high ahead of US jobs

Today 12:13

Syncona investee Gyroscope postpones US IPO citing "market conditions"

Syncona investee Gyroscope postpones US IPO citing "market conditions"

Today 09:23

Syncona's Gyroscope Therapeutics postpones IPO

(Sharecast News) - Syncona portfolio company Gyroscope Therapeutics Holdings has postponed plans for its initial public offering in light of current market conditions, the healthcare firm said on Friday.

Today 07:31

Syncona's Gyroscope Therapeutics progressing towards US float

Syncona's Gyroscope Therapeutics progressing towards US float

4 May 21 10:25

Syncona's Gyroscope Therapeutics files for potential US IPO

Syncona's Gyroscope Therapeutics files for potential US IPO

19 Apr 21 09:53

IN BRIEF: Syncona director and CIO sell GBP1.6 million in shares

IN BRIEF: Syncona director and CIO sell GBP1.6 million in shares

6 Apr 21 17:26

TRADING UPDATES: 4D Pharma loss widens on rise in administrative costs

TRADING UPDATES: 4D Pharma loss widens on rise in administrative costs

1 Apr 21 12:00

Syncona says Achilles stake leaps to GBP145 million value after IPO

Syncona says Achilles stake leaps to GBP145 million value after IPO

31 Mar 21 09:18

Achilles Therapeutics prices IPO at $175m as Syncona keeps 27% stake

(Sharecast News) - Syncona portfolio biopharma company Achilles Therapeutics said its US initial public offering (IPO) will raise $175.5m (£127.8mln).

31 Mar 21 07:41

DIRECTOR DEALINGS: Gym Group directors sell GBP1.8 million in shares

DIRECTOR DEALINGS: Gym Group directors sell GBP1.8 million in shares

30 Mar 21 16:01

Syncona invests USD42 million into Gyroscope to have 54% stake

Syncona invests USD42 million into Gyroscope to have 54% stake

26 Mar 21 09:20

Syncona invests £31m in Gyroscope

(Sharecast News) - Syncona has invested $42.3m (£31m) in Gyroscope Therapeutics as part of a $148m financing by the retinal gene therapy company.

26 Mar 21 07:59

Syncona portfolio firm Achilles Therapeutics prices US share offering

Syncona portfolio firm Achilles Therapeutics prices US share offering

25 Mar 21 12:23

TRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance

TRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance

4 Mar 21 12:46

IN BRIEF: Syncona investee Achilles Therapeutics files for US IPO

IN BRIEF: Syncona investee Achilles Therapeutics files for US IPO

2 Mar 21 13:45

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.